Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in heart failure with preserved ejection fraction
2018-003441-42Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change from baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score. Started Feb 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2018-003441-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003441-42.